1. Introduction {#sec1}
===============

Ginseng is a perennial plant belonging to the genus *Panax* and has been reported to exhibit a wide range of pharmacological and physiological actions [@bib1]. American ginseng (AG) is a popular dietary supplement and one of the most commonly used herbal medicines in the USA, which grows as *Panax quinquefolius* L. (Araliaceae) in the USA and Canada. By contrast, *Panax ginseng* Meyer (Araliaceae) has been mainly cultivated in Asia (most notably in Korea and China), and has been used extensively in traditional Chinese medicine [@bib2; @bib3]. Both AG and Asian ginseng extracts have been reported to exhibit free radical scavenging activities, which, from different ginseng species and specific parts, have been thought to be related to their ginsenoside contents [@bib4].

Ginsenosides, which are 30-carbon glycosides derived from the triterpenoid dammarane, as shown in [Fig. 1](#fig1){ref-type="fig"}, are regarded as the main active components in AG, as well as Asian ginseng. We previously identified that the structural changes in ginsenosides by heat-processing are closely associated with increased free radical-scavenging activities of AG and Asian ginseng [@bib5; @bib6]. Moreover, we have also recently reported the increased anticancer efficacy of ginsenosides derived from heat-processed Asian ginseng in human gastric cancer cells [@bib7]. Although some of the studies of AG have focused on the antiproliferative activities in cancer cells [@bib8], little is known about the effect of heat processing on the anticancer effect and mechanism of AG on gastric cancer.

Gastric cancer is the second most common cause of cancer-related deaths in the world and is estimated that over 738,000 people die from it every year [@bib9]. Multiple therapeutic strategies are used across the world for the management of operable gastric cancer patients [@bib10]. Various multimodality approaches using chemotherapy, radiation, or a combination of both have been evaluated in an attempt to improve the outcomes of postsurgery. Although there have been advances in the treatment of early gastric cancer, outcomes still remain poor with the majority of patients eventually dying from disease relapse [@bib10].

The present study sought to investigate the anticancer effect of heat-processed AG in human gastric cancer cells with a focus on assessing the role of apoptosis as important mechanistic elements in its anticancer actions.

2. Materials and methods {#sec2}
========================

2.1. Chemicals and reagents {#sec2.1}
---------------------------

Ginsenoside standards Rb1, Rb2, Rc, Rd, Re, 20(*S*)-Rg3, 20(*R*)-Rg3, Rk1, and Rg5 were purchased from Ambo Institute (Seoul, South Korea). Benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone (Z-VAD-fmk) was purchased from BioVision Inc. (Milpitas, CA, USA). Monoclonal antibodies against cleaved caspase-8 and β-actin and polyclonal antibodies against cleaved caspase-3, cleaved caspase-9, Bcl-2, Bax, and poly(ADP-ribose) polymerase (PARP) were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). Other chemicals and reagents were of high quality and obtained from commercial sources.

2.2. Preparation of ginseng extracts {#sec2.2}
------------------------------------

American ginseng extract was purchased from Sigma-Aldrich (St Louis, MO, USA). Heat-processed AG (HAG) was made by steaming AG extract at 120°C and 0.11 MPa for 3 h, and drying at 50°C for 3 d. Heat-processing condition was chosen according to the literature [@bib11]. HAG extract (30 g) was resuspended in water and the water-soluble polysaccharide fraction was separated by Diaion HP 20 (Mitsubishi Chemical, Tokyo, Japan) column chromatography using water as an eluting solution, followed by elution with methanol [@bib12]. Each solution was evaporated *in vacuo* to give the water eluate (27 g) and methanol eluate (3 g).

2.3. Analysis and structural confirmation of ginsenosides {#sec2.3}
---------------------------------------------------------

Analytical reversed-phase high performance liquid chromatography (HPLC) system was composed of a solvent degasser (G1322A; Agilent, Palo Alto, CA, USA), binary pump (G1312C; Agilent), an autosampler (G1329B; Agilent), and model 380 Evaporative Light Scattering Detector (ELSD; Agilent). ELSD conditions were optimized in order to achieve maximum sensitivity: temperature of the nebulizer was set for 50°C, and N~2~ was used as the nebulizing gas at a pressure of 2.0 bar. The Phenomenex Luna C18 column (150 mm × 4.6 mm, 5 μm, Torrance, CA, USA) was used, and the mobile phase consisted of a binary gradient of solvent A (acetonitrile:water:5% acetic acid in water = 15:80:5) and solvent B (acetonitrile:water = 80:20) at a flow rate of 1.0 mL/min. The gradient flow program was as follows: initial; 0% B, 6 min; 30% B, 18 min; 50% B, 30 min; 100% B, 37 min; 100% B, 42 min; 0% B. The amounts of ginsenosides in samples were quantified as reported previously [@bib5]. The standard solutions containing 1--50 μg of each ginsenoside were injected into the HPLC and all calibration curves showed good linearity (R^2^ \> 0.995). The analysis was repeated twice for the verification of repeatability.

2.4. Cell culture {#sec2.4}
-----------------

The human gastric cancer AGS cell line was purchased from the American Type Culture Collection (Manassas, VA, USA). The cells were grown in RPMI1640 medium (Cellgro, Manassas, VA, USA) supplemented with 10% fetal bovine serum (Gibco BRL, Carlsbad, MD, USA), 100 units/mL penicillin, and 100 μg/mL streptomycin and incubated at 37°C in a humidified atmosphere with 5% CO~2~.

2.5. Analysis of cell viability {#sec2.5}
-------------------------------

AGS cells were treated with different concentrations of compounds for 24 h, and cell proliferation was measured using the Cell Counting Kit-8 (CCK-8; Dojindo Laboratories, Kumamoto, Japan) according to the manufacturer\'s recommendations. Control cells were exposed to culture media containing 0.5% (v/v) DMSO. Paclitaxel was used as a positive control (data not shown). In order to examine the possible effects of ginsenosides on caspase-dependent apoptosis, AGS cells were also pretreated with 20 μM, 40 μM, and 60 μM Z-VAD-fmk for 2 hours prior to ginsenosides treatment.

2.6. Western blotting analysis {#sec2.6}
------------------------------

AGS cells were grown in 6-well plates and treated with the indicated concentration of compounds for 24 h. Whole-cell extracts were then prepared according to the manufacturer\'s instructions using RIPA buffer (Cell Signaling Technology, Inc.) supplemented with 1 × protease inhibitor cocktail and 1 mM phenylmethylsulfonyl fluoride. Proteins (whole-cell extracts, 30 μg/lane) were separated by electrophoresis in a precast 4--15% Mini-PROTEAN TGX gel (Bio-Rad, Hercules, CA, USA) blotted onto PVDF transfer membranes and analyzed with epitope-specific primary and secondary antibodies. Bound antibodies were visualized using ECL Advance Western Blotting Detection Reagents (GE Healthcare, Amersham, Buckinghamshire, UK) and a LAS 4000 imaging system (Fujifilm, Tokyo, Japan).

2.7. Statistical analysis {#sec2.7}
-------------------------

Statistical significance was determined through analysis of variance (ANOVA) followed by a multiple comparison test with a Bonferroni adjustment. A *p-*value of \<0.05 was considered statistically significant. The analysis was performed using SPSS version 19.0 (SPSS Inc., Chicago, IL, USA).

3. Results and discussion {#sec3}
=========================

Many bioactive dietary agents are used alone or as adjuncts to existing chemotherapy to improve efficacy and reduce drug-induced toxicity [@bib13]. For example, epidemiological, as well as experimental studies have shown that diets rich in vegetables and fruit are chemotherapeutically beneficial, exerting the activity to inhibit proliferation and induce apoptosis against malignancies, including gastric cancer [@bib14; @bib15; @bib16]. In the present study, we sought to identify the anticancer effect and mechanism of HAG to examine its therapeutic potential.

The HPLC chromatogram of AG extract is illustrated in [Fig. 2](#fig2){ref-type="fig"}. AG include the typical ginsenosides Re, Rg1, Rb1, Rc, Rb2, and Rd ([Fig. 2](#fig2){ref-type="fig"}A). After heat processing at 120°C, the ginsenosides Rb1 and Re were markedly decreased, whereas the peaks of less polar ginsenosides (20(*S*,*R*)-Rg3, Rk1, and Rg5) were newly detected at about 23 min and 27 min ([Fig. 2](#fig2){ref-type="fig"}B, [Table 1](#tbl1){ref-type="table"}). Therefore, ginsenosides Rb1 and Re were more efficiently deglycosylated and transformed into less polar ginsenosides during heat processing than other ginsenosides contained in AG.

[Fig. 3](#fig3){ref-type="fig"}A shows the morphological changes of human gastric cancer AGS cell treated with AG or HAG. The AGS cell line has been shown to grow in athymic mice and to have the same histochemical and cytological characteristics as the specimen taken from the patient [@bib15], and recently, this cell line has been widely used as a model system for evaluating cancer cell apoptosis [@bib17; @bib18]. As a result, HAG was found to induce apoptotic body formation stronger than AG ([Fig. 3](#fig3){ref-type="fig"}A), and HAG significantly suppressed AGS cell proliferation from a lower concentration, whereas AG did not suppress cell proliferation at any concentration ([Fig. 3](#fig3){ref-type="fig"}B). In addition, we prepared water and methanol eluates from HAG ([Fig. 3](#fig3){ref-type="fig"}C) to assess their cell proliferation ability, as well as to find out the main active component. As a result, the methanol eluate almost completely suppressed the cell proliferation from a concentration of 50 μg/mL, although there was no suppression in the water eluate ([Fig. 3](#fig3){ref-type="fig"}D). It has been shown that a high concentration of the ginsenosides protopanaxidiol and protopanaxatriol are eluted in methanol fraction [@bib19], suggesting that this antiproliferating activity of the methanol eluate was due to ginsenosides.

Next, we examined the antiproliferating efficacies of ginsenosides Rb1 and Re with or without heat-processing, because the amounts of these ginsenosides were decreased markedly after heat-processing in AG than in other ginsenosides ([Fig. 2](#fig2){ref-type="fig"}A). Both ginsenosides Re and Rb1 showed no efficacy in cancer cell proliferation ([Fig. 4](#fig4){ref-type="fig"}) without heat-processing. However, heat processed-Rb1 significantly suppressed cell proliferation from a lower concentration ([Fig. 4](#fig4){ref-type="fig"}A), and this result was similarly observed in the case of methanol elute ([Fig. 3](#fig3){ref-type="fig"}D). By contrast, ginsenoside Re showed a weak efficacy even at a high concentration of 100 μg/mL ([Fig. 4](#fig4){ref-type="fig"}B). Therefore, the major active component of HAG was considered to be related to heat-processed ginsenoside Rb1. From the HPLC analysis of ginsenoside Rb1, prior to and after heat-processing, ginsenoside Rb1 was transformed into ginsenosides 20(*S*,*R*)-Rg3, Rk1, and Rg5 after heat-processing at 120°C ([Fig. 4](#fig4){ref-type="fig"}Cand D) as shown in AG ([Fig. 2](#fig2){ref-type="fig"}). We previously reported that ginsenoside Re gradually transformed into less polar ginsenosides Rg2, Rg6, and F4 upon heat-processing [@bib7]. Considering these, less polar ginsenosides 20(*S*,*R*)-Rg3, Rk1, and Rg5 in HAG were generated mainly from ginsenoside Rb1 by heat processing at 120°C.

We next examined the antiproliferative effects of 20(*S*,*R*)-Rg3 or Rk1/Rg5 mixtures, which were collected using preparative HPLC. As shown in Fig. 5A, 5B, 20(*S*,*R*)-Rg3 reduced cancer cell viability stronger than Rk1/Rg5 mixture, and each IC~50~ value were 23.6 μg/mL and 42.9 μg/mL, respectively. Interestingly, the efficacy of 20(*S*,*R*)-Rg3 was similar with that of the methanol eluate, as well as of heat-processed Rb1 (Figs. [3](#fig3){ref-type="fig"}D and [4](#fig4){ref-type="fig"}A). To further confirm the main active component, anticancer effects of 20(*S*)-Rg3 and 20(*R*)-Rg3 were individually examined. Subsequently, ginsenoside 20(*S*)-Rg3 was obviously identified as the main active component of HAG, while there was no effect in ginsenoside 20(*R*)-Rg3 ([Fig. 5](#fig5){ref-type="fig"}C and D). Thus, anticancer efficacy of HAG was thought to be mainly related to ginsenoside 20(*S*)-Rg3, which was transformed from ginsenoside Rb1 during heat processing.

Apoptosis is recognized as an essential mechanism of physiological cell death, and caspases play pivotal roles in cell apoptosis. In line with this notion, we investigated whether ginsenoside 20(*S*)-Rg3-induced cell death is involved in apoptosis. A Western blot analysis was first used to evaluate the expression of proteins involved in the apoptotic response to determine if apoptosis occurs via the intrinsic or extrinsic pathway ([Fig. 6](#fig6){ref-type="fig"}A--C). Exposure to ginsenoside 20(*S*)-Rg3 for 24 h induced the cleavage of PARP, as well as that of caspase-3, caspase-8, and caspase-9, in a dose-dependent manner. In addition, ginsenoside 20(*S*)-Rg3 significantly triggered the downregulation of Bcl-2 and upregulation of Bax in a dose-dependent manner. Next, we examined the effect of the pan-caspase inhibitor Z-VAD-fmk on cell proliferation to confirm the role played by caspases in ginsenoside 20(*S*)-Rg3-induced apoptosis. As shown in [Fig. 6](#fig6){ref-type="fig"}D, pretreatment with 60 μM Z-VAD-fmk abrogated apoptotic cell death induced by the ginsenoside 20(*S*)-Rg3, although the recovery was weak at the high concentration of 50 μg/mL. These findings demonstrate that ginsenoside 20(*S*)-Rg3 induces the activation of caspase-3, caspase-8, and caspase-9, which contributes to apoptotic cell death.

Ginsenosides 20(*S*)-Rg3 and 20(*R*)-Rg3 are epimers of each other depending on the position of the hydroxyl group (OH) on carbon-20 ([Fig. 1](#fig1){ref-type="fig"}), and this epimerization is known to be produced by the selective attack of the OH group after the elimination of glycosyl residue at carbon-20 during the steaming process [@bib20]. In the present study, 20(*S*)-Rg3 showed stronger anticancer activity than 20(*R*)-Rg3. Therefore, stereospecificity exists in the anticancer activity of ginsenoside Rg3 epimers. In addition, stereospecificity in the medicinal efficacy of these ginsenosides has been reported by several researchers. The OH group of ginsenoside 20(*S*)-Rg3 is better aligned with that of the OH acceptor group in the ion channels than that of ginsenoside 20(*R*)-Rg3, and thus important for Na^+^ channel regulation [@bib21]. Ginsenoside 20(*S*)-Rg3 was also reported to provide neuroprotection against cerebral ischemia-induced injury in rat brain through reducing lipid peroxides and scavenging free radicals [@bib22].

In summary, our results suggest that heat-processing improves antitumor activity of AG in AGS cells, and ginsenoside 20(*S*)-Rg3 serves as a major component through activation of caspase-3, caspase-8, and caspase-9 in the event.
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![Structures of ginsenosides contained in American ginseng. --Glc, D-glucopyranosyl; -Rha, L-rhamnopyranosyl; -Ara(f), L-arabinofuranosyl; -Ara(p), L-arabinopyranosyl.](gr1){#fig1}

![Comparison of HPLC chromatograms. (A) American ginseng; and (B) heat-processed American ginseng. HPLC, high performance liquid chromatography.](gr2){#fig2}

![Changes in effects of American ginseng upon heat-processing on AGS cell proliferation. (A) Morphological changes were confirmed using phase-contrast microscopy. (B) Cells were treated with American ginseng with or without heat-processing at different concentrations (150 μg/mL, 300 μg/mL, and 600 μg/mL) for 24 h. Relative cell proliferation was measured by the CCK-8 assay. Each value represents the mean ± standard deviation of three independent experiments. (C) Schematic description for the preparation of methanol-soluble fraction with HP 20 column chromatography. (D) Cells were treated with water eluate or methanol eluate at different concentrations (12.5 μg/mL, 25 μg/mL, 50 μg/mL, and 100 μg/mL) for 24 h. Relative cell proliferation was measured by the CCK-8 assay. Each value represents the mean ± standard deviation of three independent experiments. \**p* \< 0.05 compared with the vehicle control. CCK-8, Cell Counting Kit-8.](gr3){#fig3}

![Changes in effects of ginsenosides Rb1 and Re upon heat-processing on AGS cell proliferation. (A) Cells were treated with ginsenoside Rb1 or heat-processed ginsenoside Rb1 at different concentrations (12.5 μg/mL, 25 μg/mL, 50 μg/mL, and 100 μg/mL) for 24 h. (B) Cells were treated with ginsenoside Re or heat-processed ginsenoside Re at different concentrations (12.5 μg/mL, 25 μg/mL, 50 μg/mL, and 100 μg/mL) for 24 h. Relative cell proliferation was measured by the CCK-8 assay. Each value represents the mean ± standard deviation of three independent experiments. (C) HPLC chromatogram of ginsenoside Rb1 prior to heat-processing. (D) HPLC chromatogram of ginsenoside Rb1 after heat-processing. \**p* \< 0.05 compared with vehicle control. CCK-8, Cell Counting Kit-8; HPLC, high performance liquid chromatography.](gr4){#fig4}

![Anticancer effects of ginsenosides on AGS cell proliferation. (A) Cells were treated with ginsenoside 20(*S,R*)-Rg3 at different concentrations (12.5 μg/mL, 25 μg/mL, 50 μg/mL, and 100 μg/mL) for 24 h. (B) Cells were treated with ginsenoside Rg5/Rk1 at different concentrations (12.5 μg/mL, 25 μg/mL, 50 μg/mL, and 100 μg/mL) for 24 h. (C) Cells were treated with ginsenoside 20(*S*)-Rg3 at different concentrations (6.25 μg/mL, 12.5 μg/mL, 25 μg/mL, 50 μg/mL, and 100 μg/mL) for 24 h. (D) Cells were treated with ginsenoside 20(*R*)-Rg3 at different concentrations (6.25 μg/mL, 12.5 μg/mL, 25 μg/mL, 50 μg/mL, and 100 μg/mL) for 24 h. Relative cell proliferation was measured by the CCK-8 assay. Each value represents the mean ± standard deviation of three independent experiments. \**p* \< 0.05 compared with the vehicle control. CCK-8, Cell Counting Kit-8.](gr5){#fig5}

![Effect of ginsenoside 20(*S*)-Rg~3~ on apoptosis in AGS cells. Western blotting results for (A) extrinsic and (B) intrinsic apoptosis in AGS cells showing the levels of cleaved caspase-8 (18 kDa), Bcl-2 (26 kDa), Bax (20.5 kDa), cleaved caspase-9 (35, 37 kDa), cleaved caspase-3 (17 kDa, 19 kDa), PARP (116 kDa), and cleaved PARP (85 kDa) in AGS cells treated with ginsenoside 20(*S*)-Rg3 at different concentrations (12.5 μg/mL, 25 μg/mL, and 50 μg/mL) for 24 h. Thirty micrograms of each protein were separated by SDS-PAGE. Beta-actin (45 kDa) was used as an internal control. (C) The panel is the bar graph representing the relative density of cleaved caspase-8, cleaved capase-9, cleaved caspase-3, PARP, Bcl-2, and Bax. The values were normalized with β-actin. (D) Cells were pretreated with the different concentrations (20 μM, 40 μM, and 60 μM) of Z-VAD-fmk for 2 h, followed by exposure to ginsenoside 20(*R*)-Rg3 at different concentrations (6.25 μg/mL, 12.5 μg/mL, 25 μg/mL, 50 μg/mL, and 100 μg/mL) for 24 h. Relative cell proliferation was measured by the CCK-8 assay. Each value represents the mean ± standard deviation of three independent experiments. \**p* \< 0.05 compared with the ginsenoside 20(*S*)-Rg3-treated value. CCK-8, Cell Counting Kit-8; PARP, poly(ADP-ribose) polymerase; Z-VAD-fmk, Benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone.](gr6){#fig6}

###### 

Changes in contents of ginsenosides (μg/mg)

        Re    Rb1    Rc    Rb2   Rd    20(*S*)-Rg3   20(*R*)-Rg3   Rk1   Rg5
  ----- ----- ------ ----- ----- ----- ------------- ------------- ----- -----
  AG    5.1   15.5   1.3   0.9   2.4   ---           ---           ---   ---
  HAG   ---   2.0    ---   2.2   3.0   11.3          3.9           2.9   3.6

AG, American ginseng; HAG, heat-processed American ginseng.
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